Saturday, October 05, 2024 7:33:11 AM
I am also almost certain that after milestone UK approval NWBO will disclose a cooperation with a big pharma with a big bag of cash.
However, my point was that the big pharma investing in NWBO could have done that 2 years ago after the JAMA article avoiding the risk of
A. another suiter running away with NWBO
B. making sure NWBO will not go bankrupt
Powers said at the Dec 2022 ASM that they walked away from previously held negotiations with large pharmaceutical companies because these companies expected NWBO to carry almost all of the burden and they would reap little of the profit. Didnt these companies see DCVAX's potential then?
The conclusion is that large pharmaceutical companies are willing to risk NWBO being swooped away or getting bankrupt and prefer to wait before transferring a (for them meaningless) large sum of money into NWBO's bank account until after UK approval than jump in two or one year ago.
JMO
However, my point was that the big pharma investing in NWBO could have done that 2 years ago after the JAMA article avoiding the risk of
A. another suiter running away with NWBO
B. making sure NWBO will not go bankrupt
Powers said at the Dec 2022 ASM that they walked away from previously held negotiations with large pharmaceutical companies because these companies expected NWBO to carry almost all of the burden and they would reap little of the profit. Didnt these companies see DCVAX's potential then?
The conclusion is that large pharmaceutical companies are willing to risk NWBO being swooped away or getting bankrupt and prefer to wait before transferring a (for them meaningless) large sum of money into NWBO's bank account until after UK approval than jump in two or one year ago.
JMO
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
